

ASPHO Meeting at a Glance



American Society of Pediatric Hematology/Oncology

Seventeenth Annual Meeting ~ April 29–May 2, 2004
Westin St. Francis Hotel and Moscone West Convention Center

Thursday, April 29	Friday, April 30	Saturday, May 1	Sunday, May 2
<p>7:30am – 8:30am ASPHO Workshops ~Immune Cytopenias ~Hemoglobinopathies</p> <p>8:45am – 9:00am ASPHO President's Welcome</p> <p>9:00am – 11:00am ASPHO Symposium I ~Non-immune Thrombocytopenia</p> <p>11:00am – 11:30am Break</p> <p>11:30am – 12:30pm 3rd Annual Frank A. Oski Memorial Lecture ~Hydroxyurea for Children with Sickle-Cell Disease: Fact, Fiction and Fantasy</p> <hr/> <p>12:30pm – 2:30pm ASPHO Corporate Forum Luncheons</p> <hr/> <p>2:30pm – 3:00pm Dessert Break with Exhibits</p> <p>3:00pm – 5:00pm ASPHO Presidential Symposium ~Genetic Predisposition to Leukemia</p> <p>5:00pm – 6:30pm ASPHO Opening Reception and Exhibits</p> <hr/> <p>7:00pm – 9:00pm ASPHO Corporate Forum Dinners</p>	<p>7:15am – 8:15am ASPHO Workshops ~Thrombosis ~Practice Management</p> <p>8:30am – 10:30am ASPHO Symposium II ~Neuroblastoma</p> <p>10:30am – 11:00am Break with Exhibits</p> <p>11:00am – 12:00 noon ASPHO Workshops ~Non-immune Cytopenias ~Histiocytosis</p> <hr/> <p>12:00 noon – 2:00pm ASPHO Corporate Forum Luncheons</p> <hr/> <p>2:00pm – 4:30pm ASPHO Symposium III ~Myelodysplastic Syndromes in Pediatrics</p> <p>4:30pm – 5:00pm ASPHO Distinguished Career Award Presentation</p> <p>5:00pm – 5:30pm ASPHO Business Meeting</p> <p>5:30pm – 6:00pm ASPHO Distinguished Career Award Reception</p>	<p>7:30am – 8:30am ASPHO Workshops ~Young Investigator ~Pediatric Cancer ~Hemorrhagic Disorders ~Cancer Survivorship</p> <div style="border: 1px solid black; border-radius: 50%; padding: 10px; text-align: center; margin: 10px auto; width: 80%;"> <p>PAS/ASPHO Joint Programming Begins ~ Moscone West Convention Center</p> </div> <p>9:15am – 12:15pm PAS/ASPHO Mini Courses ~Immunology 101 ~Innovations in Transfusion Medicine ~Novel Targets and Novel Drugs – Peering Through the Pharmaceutical Pipeline</p> <hr/> <p>11:45am – 2:45pm PAS Mini Course ~Pain and Symptom Management in Pediatric Palliative and End-of-Life Care</p> <p>1:00pm – 3:00pm PAS/ASPHO Original Science Abstracts ~Hematology/Oncology Platform Session I</p> <p>3:15pm – 5:15pm PAS/ASPHO Topic Symposium ~Disorders of Neutrophil Number and Function</p> <p>5:15pm – 7:15pm PAS/ASPHO Posters I, Exhibits and PAS Opening Reception ~Hematology/Oncology Posters</p>	<p>7:00am – 8:00am Meet the Professor Breakfast ~Hematology/Oncology</p> <p>8:00am – 10:00am PAS/ASPHO Original Science Abstracts ~Hematology/Oncology Platform Session II</p> <p>10:15am – 11:45am PAS/ASPHO Original Science Abstracts ~Hematology/Oncology Platform Session III</p> <hr/> <p>11:45am – 1:45pm PAS/ASPHO Posters II and Exhibits ~Hematology/Oncology Posters</p> <hr/> <p>2:00pm – 4:00pm PAS/ASPEN/LWPES/PIDS Topic Symposium ~Complications Following Solid Organ Transplantation</p> <p>2:30pm – 4:00pm PAS/ASPHO/PIDS State of the Art Plenary ~Infections of the Immunocompromised Host</p> <p>4:15pm – 6:15pm PAS/ASPHO Topic Symposium ~Emerging Trends in HSCT for Immunodeficiencies</p>

ASPH/O

The American Society of
Pediatric Hematology/Oncology

Join us in San Francisco, where ASPHO and PAS will host aligned annual meetings. Joint symposia and original science abstracts will all be held at the Moscone West Convention Center. We look forward to the synergy created by this alliance. The ASPHO Annual Meeting will be hosted at the Westin St. Francis Hotel just prior to the PAS.

Registration Information

Please read the registration instructions carefully.

If you are a member of APS, SPR or APA, please register for the PAS meeting. The PAS registration form on page 95 includes an option to indicate that you will attend the ASPHO program. You will be allowed access to the programming at the ASPHO meeting at no additional registration fee with your PAS badge. Contact PAS for further details at info@pas-meeting.org, register on-line at www.pas-meeting.org or call 281-419-0052.

If you are a member of ASPHO and/or a pediatric hematologist / oncologist and wish to attend the ASPHO meeting, please register directly with ASPHO. The ASPHO registration form includes an option to indicate that you will attend the PAS programming. Your registration will be forwarded to PAS, and you will be entitled to attend the ASPHO program, the joint programming and the PAS program offerings with your ASPHO badge at no additional registration fee or process. Contact ASPHO to register or to request program materials (847-375-4716; info@aspho.org; www.aspho.org).

Confirmation

You will receive separate confirmations for each meeting. If you register for ASPHO and indicate your attendance at the PAS meeting, you will receive confirmation from both organizations.

Contact ASPHO for further details on the ASPHO Annual Meeting:

American Society of Pediatric Hematology/Oncology

4700 W. Lake, Glenview, IL 60025-1485

Phone: 847-375-4716

Fax: 877-734-9557

Email: info@aspho.org

URL: www.aspho.org

Housing Information

ASPHO has chosen the **Westin St. Francis** for its meeting headquarters with a special negotiated rate for this meeting. Be sure to mention you are attending the ASPHO 17th Annual Meeting to receive the special rate. Make your reservations (phone numbers listed below) EARLY to ensure you obtain the special room rates. After **March 29, 2004**, the ASPHO rate is not guaranteed, and higher rates may apply.

The Westin St. Francis

335 Powell Street

San Francisco, CA 94102-1875

Phone: 415-397-7000

Reservations: 800-WESTIN 1

Cut-off Date: March 29, 2004

Rate: \$239-\$259 single/double

Program Purpose

The 17th Annual Meeting of The American Society of Pediatric Hematology/Oncology will present current data from research concerning causes, diagnosis and management of hematology/oncology problems in children and will apply it to clinical practice.

Conference Objectives

The 17th Annual Meeting will help participants to:

- Discuss the latest advances in understanding the pathophysiology and molecular basis for non-immune thrombocytopenia.
- Discuss the potential application of hydroxyurea for treating children with sickle-cell disease.
- Discuss current concepts and research in identifying potential genetic predispositions to leukemia.
- Describe current therapies and novel strategies for treating neuroblastoma in children.
- Describe the classification of MDS and discuss current therapies for treating MDS in children.
- Assemble a network of professional colleagues with common interests to solve problems, share experiences in the setting of interactive workshops, and provide mutual professional support.

Continuing Education Credit

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Tulane University Health Sciences Center and the Pediatric Academic Societies. Tulane University Health Sciences Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Tulane University Health Sciences Center designates this educational activity for a maximum of 50.75 credits in category 1 toward the AMA Physician's Recognition Award (**13 credits maximum for ASPHO sessions; 38.25 credits maximum for PAS sessions**). Each physician should claim only those credits that he/she actually spent in the educational activity.

The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA category 1 credit.

Tulane University Health Sciences Center presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected because of their recognized expertise.

It is the policy of the Center for Continuing Education at Tulane University Health Sciences Center to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in these programs are expected to disclose to the program audiences any real or apparent conflict of interest related to the contents prior to their presentations. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers or other corporations whose products or services are related to the subject matter of the presentation topic, including off-label, experimental or investigational use of drugs or devices. Full disclosure of faculty relationships will be published in the ASPHO Program Book, available at the ASPHO Registration Desk.

How to Obtain CME Credit

If registered through ASPHO, CME credit for the ASPHO program is included in your registration fee. No additional fee will be required to receive CME credit for attending the ASPHO sessions or the joint PAS/ASPHO sessions. To receive credit for attending the conference, please note the following:

1. CME verification forms will be provided with the evaluation booklets included in each ASPHO registration packet. Extra forms and booklets will be available at the ASPHO registration desk at the Westin St. Francis.
2. Complete the CME verification form. Be sure to indicate all sessions that you attended.
3. Turn in your completed CME verification form to the ASPHO registration desk at the Westin St. Francis before you leave the conference or at the PAS CME desk at the Moscone West Convention Center.

ASPH/O

ASPHO Programming on
Thursday, Friday and Saturday morning is at the
Westin St. Francis Hotel.

Thursday, April 29

7:30am – 8:30am

Immune Cytopenias Workshop

Co-chairs: Victor S. Blanchette, The Hospital for Sick Children, Toronto, ON, Canada; and Thomas Kuehne, University Children's Hospital, Basel, Switzerland

This workshop will present updates and reports on newer therapies for the treatment of immune cytopenias in children.

Hemoglobinopathies Workshop

Co-chairs: Russell Ware, Duke University Medical Center, Durham, NC; and Matthew M. Heeney, Boston Children's Hospital, Boston, MA

Improved understanding of the pathophysiology of vaso-occlusion in sickle-cell disease has led to the potential for therapeutic intervention at multiple and distinct points. This workshop will provide an overview of therapeutic options for children with sickle-cell disease, including currently available treatments and new or potential treatments.

8:45am – 9:00am

President's Welcome

Beverly Lange, ASPHO President, Children's Hospital of Philadelphia, Philadelphia, PA

9:00am – 11:00am

Symposium on Non-immune Thrombocytopenia

Moderator: Diane Nugent, Children's Hospital of Orange County, Orange, CA

This symposium will cover the latest developments in the pathophysiology and molecular basis for this rapidly expanding category of platelet disorders. The session will focus on inherited forms of thrombocytopenia that result in either abnormal production or consumption of platelets. Four major areas in this category are now recognized as the leading etiologies of non-immune thrombocytopenia in children and will be discussed by leaders in this field.

Introduction

Congenital Thrombocytopenia, Thrombopoietin and the Hematopoietic Stem Cell

Kenneth Kaushansky, University of California at San Diego Cancer Center, San Diego, CA

Giant Platelet Syndromes

John A. Martignetti, Mount Sinai School of Medicine, New York, NY

Congenital Platelet Signaling Defects

A. Koneti Rao, Temple University Medical School, Philadelphia, PA

ADAMTS 13 Gene Mutation in Congenital Thrombotic Thrombocytopenic Purpura

David Ginsburg, University of Michigan Medical School, Ann Arbor, MI

Question and Answer/Panel Discussion

11:00am – 11:30am

Break

11:30am – 12:30pm

Hydroxyurea for Children with Sickle-Cell Disease: Fact, Fiction, and Fantasy

3rd Annual Frank A. Oski Memorial Lecture

Russell Ware, Duke University Medical Center, Durham, NC

Hydroxyurea is the only FDA-approved therapy for persons with sickle-cell anemia, but it is not currently approved for children. Available data suggest hydroxyurea has remarkable hematological and clinical efficacy for young patients, however. Various aspects of hydroxyurea therapy will be discussed, including the rationale for treatment, proposed mechanisms of action, dose titration, appropriate clinical settings, short-term risks and benefits, and long-term effects. The importance of translational research projects to help answer important questions about the use of hydroxyurea in children with sickle-cell disease will be emphasized.

12:30pm – 2:30pm

Corporate Forum Luncheons

These sessions are commercially supported events. Pre-registration is required by responding to the invitation sent to all ASPHO members by the supporting company.

Hemophilia A Challenges in Pediatric Patients: Today and the Future of Treatments

Robert L. Janko, Vanderbilt University, Nashville, TN; and Bertil E. Glader, Stanford University, Palo Alto, CA

In hemophilia A, there are a number of choices we must make as clinicians. The first section of the program will look at available therapy options, examine if there are requirements for product choices, and address challenges confronting the family. In the second half of the program, we will look at potential new trials with a focus on gene therapy.

Supported by an unrestricted educational grant from Aventis Behring

Expanding Clinical Options for the Treatment of Pediatric Acute Leukemia

Basem Razzouk, St. Jude Children's Research Hospital, Memphis, TN; Ka Wah Chan, UT MD Anderson Cancer Center, Houston, TX; Richard Kadota, Children's Hospital of San Diego, San Diego, CA; Peter Adamson, Children's Hospital of Philadelphia, Philadelphia, PA; Sima Jeha, St. Jude's Children's Research Hospital, Memphis, TN; and Robert Arceci, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Currently there are limited treatment options available for pediatric acute leukemia patients, especially those with relapsed or primary refractory disease. New therapies are needed to treat pediatric patients with an unmet medical need. This forum will present two panel discussions to help participants define current treatment options for pediatric acute leukemias, determine the best treatment algorithms for individual patients, and bring a multidisciplinary team approach to patients with relapsed, refractory disease.

Supported by an unrestricted educational grant from ILEX Oncology, Inc.

2:30pm – 3:00pm

Dessert Break with Exhibits

ASPHO Programming

3:00pm – 5:00pm

Genetic Predisposition to Leukemia

Presidential Symposium

Moderator: Beverly Lange, Children's Hospital of Philadelphia, Philadelphia, PA

The primary objective of this symposium is to gain an understanding of the pathogenesis of leukemia in children with constitutional disorders that predispose to leukemia. We will address those involving the RAS activation, such as neurofibromatosis type 1 and Noonan's syndrome, Fanconi's anemia, and Down's syndrome. How these relatively rare disorders contribute to the pathogenesis of leukemia and other cancers in constitutionally normal children will be discussed. Participation in an interactive pop-quizz will help the audience recognize constitutional disorders that predispose to leukemia.

Nf-1, Noonan's and Inherited and Acquired Disorders of RAS Pathway Activation in JMML, MDS, and AML

Kevin M. Shannon, UCSF Comprehensive Cancer Center, San Francisco, CA

Leukemia in Down's Syndrome

John Crispino, University of Chicago, The Ben May Institute, Chicago, IL

Fanconi Anemia

Alan D. D'Andrea, Dana Farber Cancer Institute, Boston, MA

Review

5:00pm – 6:30pm

ASPHO Opening Reception and Exhibits

7:00pm – 9:00pm

Corporate Forum Dinners

These sessions are commercially supported events. Pre-registration is required by responding to the invitation sent to all ASPHO members by the supporting company.

Issues in ALL: Evolution and Advances in Pediatric Treatment

Greg Reaman, Children's National Medical Center, Washington, DC; Nita Seibel, Children's National Medical Center, Washington, DC; Vassilios Avramis, University of Southern California, Los Angeles, CA; and Elizabeth Raetz, Mount Sinai Hospital, New York, NY

ALL is the most common cancer occurring in children, representing 23% of cancer diagnoses among children younger than 15 years. With current therapies, 75%–80% of children with ALL survive free of leukemia at least 5 years from diagnosis. Despite previous treatment advances, many important biologic and therapeutic questions remain. This symposium will focus on information on clinical outcomes from therapy with pegylated-L-asparaginase, compared with native L-asparaginase in children with high-risk ALL, and will discuss the impact of antibody development on the efficacy of therapy with L-asparaginase and the potential of genetic profiling on therapy in ALL.

Supported by an unrestricted educational grant from Enzon Pharmaceuticals

The Hemophilia Management Cascade: Optimizing Treatment Based on Patient Needs

Jeanne Lusher, Children's Hospital of Michigan, Detroit, MI; Deborah Brown, University of Texas Health Sciences Center, Houston, TX; Craig Kessler, Georgetown University Medical Center, Washington, DC; and Marilyn Manco-Johnson, Mountain States Regional Hemophilia and Thrombosis Center, Aurora, CO

The treatment of patients with hemophilia has evolved considerably during the past several years. Although many challenges these patients face have

been addressed, other issues still need to be addressed. This interactive symposium will discuss some of the many issues faced by hemophilia healthcare professionals, patients, and their families on a daily basis, and will provide an overview of inhibitor interventions, optimizing outcomes, and developing strategies for on-demand treatment, prophylaxis, and prevention.

Supported by an unrestricted educational grant from Wyeth Pharmaceuticals

Friday, April 30

7:15am – 8:15am

Thrombosis Workshop

Co-chairs: Patricia Massicotte, Hospital for Sick Children, Toronto, ON, Canada; and Lori Luchtman-Jones, Washington University School of Medicine, St. Louis, MO

This workshop will review practice strategies developed for the treatment of several common thrombotic disorders in pediatric patients and will encourage the audience to participate in the development of a rational approach to management of patients with these and other thrombotic disorders.

Practice Management Workshop

Chair: Timothy C. Griffin, Cook Children's Medical Center, Fort Worth, TX

How to Divorce Your Hospital ... or, Should This Marriage be Saved?

Instability in health care financing has created economic stresses for many pediatric hematology/oncology programs. This has led many practices to question whether their programs would be more viable in hospital-based or free-standing clinic settings. A lively panel discussion will discuss the many factors which influence this decision. Participants will identify strategies to work in concert with program administrators and assess factors leading to optimal operational and financial practice performance.

8:30am – 10:30am

Symposium on Neuroblastoma

Moderator: Valerie Castle, Comprehensive Cancer Center, Ann Arbor, MI

Despite intensive and myeloablative therapy, high-risk neuroblastoma eventually becomes resistant to treatment in more than 50% of cases, resulting in relapse and death. Mechanisms of tumor resistance are manifold, ranging from sanctuary sites, hypoxic sites, altered DNA repair, p53 mutations, and increased detoxification of alkylators. This symposium will cover the biological basis for neuroblastoma clinical heterogeneity linking clinical and laboratory observations to current risk and treatment stratifications for this disease. Novel therapies discussed will include those that attack tumor cells through mechanisms designed to overcome resistance, immunological approaches, tumor-targeted radiotherapy, interference with Trk inhibitors, anti-angiogenics, glutathione synthetase inhibitors, and novel differentiating agents. Finally, recent laboratory observations that promise to identify new molecular targets will be highlighted.

Biologic Basis for Neuroblastoma Clinical Heterogeneity and Risk Stratification

John M. Maris, Children's Hospital of Philadelphia, Philadelphia, PA

Current Therapeutic Approaches and Upcoming Novel Therapies

Katherine Kurshan Matthey, University of California, San Francisco, CA

Emerging Molecular Targets: Basic Laboratory Studies with Clinical Promise

Valerie Castle, Comprehensive Cancer Center, Ann Arbor, MI

Question and Answer Session/Panel Discussion

10:30am – 11:00am
Break with Exhibits

11:00am – 12:00pm

Non-immune Cytopenias Workshop

Co-chairs: Jeffrey D. Hord, Children's Hospital Medical Center, Akron, OH; and Adriana Vlachos, Schneider Children's Hospital, New Hyde Park, NY

This interactive workshop will encourage group discussion of several marrow failure syndrome cases. Attention will be focused on accurate diagnosis and current treatment options. Participants will be able to (1) describe how red cell ADA levels can be used in diagnosing Diamond-Blackfan anemia; (2) recognize when bone marrow/stem cell transplantation is an appropriate treatment modality for a child with acquired severe aplastic anemia; (3) recognize the heterogeneity of presentation of Fanconi anemia; and (4) identify the interventions that may be used in treating Shwachman-Diamond.

Histiocytoses Workshop

Co-chairs: Kenneth L. McClain, Texas Children's Cancer Center, Houston, TX; and Jan-Inge Henter, Karolinska University Hospital, Stockholm, Sweden

Clinical and basic research on Langerhans cell histiocytosis (LCH) presented at the 2003 Histiocyte Society meeting will be summarized as well as updates on the progress of the LCH-III protocol, salvage therapy for relapsed LCH, and the LCH-CNS study. The HLH update will summarize the results of the HLH-94 study (including the results of BMT), and it will also present the new HLH Treatment Protocol and news on Basic Research in HLH.

12:00pm – 2:00pm

Corporate Forum Luncheons

These sessions are commercially supported events. Pre-registration is required by responding to the invitation sent to all ASPHO members by the supporting company.

Treatment of Bleeding Disorders in Pediatric Patients: New Insights to Improve Patient Care

Prasad Mathew, University of New Mexico, Albuquerque, NM; Amy Shapiro, Indiana Hemophilia and Thrombosis Center, Indianapolis, IN; and Nigel Key, University of Minnesota, Minneapolis, MN

Uncontrolled bleeding episodes complicate the clinical treatment of pediatric patients. There are a number of coagulopathic diseases, including hemophilia, that can affect medical treatment of pediatric patients. This session will discuss new data from the Hemophilia Research Society registry and the impact it may have on appropriate treatment protocols for excessive bleeding and describe ongoing clinical trials with rFVIIa.

Supported by an unrestricted educational grant from NovoNordisk Pharmaceuticals, Inc.

Advances in the Treatment of Children with Leukemia and Lymphoma

Ching-Hon Pui, St. Jude Children's Research Hospital, Memphis, TN; Mitchell S. Cairo, Children's Hospital of New York-Presbyterian, New York, NY; Melissa Hudson, St. Jude Children's Research Hospital, Memphis, TN; and Stanton C. Goldman, North Texas Hospital for Children, Dallas, TX

Improved outcomes in children with hematologic malignancies are attributed to refinements in multidrug treatments, chemotherapy intensities tailored to risk, targeted therapies, and the prevention of tumor lysis syndrome. This program will provide the practitioner with data from clinical trials supporting

the implementation of these strategies in the clinical setting. The session will help participants to (1) Identify recent advances in tumor biology of childhood leukemias that may potentially affect disease management, (2) Describe newly developed treatment protocols associated with prolonged survival in children with non-Hodgkin's and Hodgkin's lymphomas, and (3) Cite clinical trial data supporting improved outcomes associated with drug therapies currently in use for the treatment and prevention of tumor lysis syndrome.

Supported by an unrestricted educational grant from Sanofi-Synthelabo, Inc.

2:00pm – 4:30pm

Symposium on Myelodysplastic Syndromes in Pediatrics

Moderator: William G. Woods, Emory University, Atlanta, GA

Myelodysplastic syndromes represent a heterogeneous class of clonal stem cell disorders that are poorly understood. This program will discuss recent developments in the treatment, classification, and underlying causes of myelodysplastic diseases in children.

Clinical Aspects of Childhood MDS

William G. Woods, Emory University, Atlanta, GA

A Pediatric Approach to Classification of MDS

David Head, Vanderbilt University Medical Center, Nashville, TN

Understanding the Pathophysiology of Marrow Failure in MDS

Neal S. Young, National Heart, Lung and Blood Institute, Bethesda, MD

Question and Answer Session

4:30pm – 5:00pm

Distinguished Career Award Presentation

5:00pm – 5:30pm

Annual Business Meeting

5:30pm – 6:00pm

Distinguished Career Award Reception

Saturday, May 1

7:30am – 8:30am

Young Investigators Workshop

Chair: Judith E. Margolin, Texas Children's Center, Houston, TX

This informal discussion will offer hematology/oncology fellows and junior faculty the opportunity to network and discuss issues of mutual interest.

Pediatric Cancer Workshop

Co-chairs: Peter A. Adamson, Children's Hospital of Philadelphia, Philadelphia, PA; and Jeffrey A. Moscow, University of Kentucky Medical Center, Lexington, KY

What's New with Neutropenia: New Approaches to Infections in the Immunocompromised Host

This session will include discussions of new antifungal agents and new approaches to neutropenic fever.

Hemorrhagic Disorders Workshop

Co-chairs: Pedro A. deAlarcon, University of Virginia, Charlottesville, VA; and Marilyn Manco-Johnson, Mountain States Regional Hemophilia Center, Aurora, CO

Workshop participants will review cases and contribute to the development of consensus guidelines for several bleeding disorders.

Cancer Survivorship Workshop

Co-chairs: H. Stacey Nicholson, Oregon Health Sciences University, Portland, OR; and Debra Friedman, Children's Hospital and Regional Medical Center, Seattle, WA

This new workshop will provide a forum for pediatric hematologists/oncologists to discuss cancer survivorship issues most relevant to their practice.

PAS/ASPHO Programming Begins at the Moscone West Convention Center

9:15am – 12:15pm

I300 Immunology 101

PAS/ASPHO Mini Course

Chairs: Beverly J. Lange, Children's Hospital of Philadelphia, Philadelphia, PA; and E. Richard Stiehm, UCLA Children's Hospital, Los Angeles, CA

There has been remarkable progress in our understanding of the development and function of the immune system in health and disease. The regulation of immunity impacts profoundly on many of the conditions that pediatricians treat. The objective of this program is to enable PAS attendees coming from diverse disciplines to understand the language of modern immunology and the translation of recent advances in basic science to the diagnosis and treatment of diseases of children. This course will address three areas: immunology of infectious diseases, immunology of auto-immunity and tumor immunology.

Immunology of Infectious Disease

Katherine F. Luzuriaga, University of Massachusetts Medical School, Worcester, MA

Immunology of Auto-immunology

Betty Diamond, Albert Einstein College of Medicine, Bronx, NY

Tumor Immunology

Robert H. Vonderheide, University of Pennsylvania, Philadelphia, PA

Sponsored jointly by the American Society of Pediatric Hematology / Oncology and the Pediatric Academic Societies

9:15am – 12:15pm

I301 Innovations in Transfusion Medicine

PAS/ASPHO Mini Course

Chairs: Naomi Luban, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC; and Guy Young, Children's Hospital of Orange County, Orange County, CA

This session will review the development and clinical usefulness of blood/blood products and derivatives used in the treatment of patients with hematologic and oncologic diseases and the bleeding patient. The role of these novel and often modified products in selected patient groups will be discussed.

Transfusion Support of the HSCT Patient

Terry Gernsheimer, Puget Sound Blood Center, Seattle, WA

Transfusion Support of the Chronically Transfused Patient with Sickle Cell Anemia

Naomi L. C. Luban, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC

Novel Therapies for Acute Bleeding

Guy Young, Children's Hospital of Orange County, Orange County, CA

Pathogen Reduction—Risks, Benefits and Hidden Benefits for GVHD

Lawrence Corash, Cerus Corporation, Concord, CA

Sponsored jointly by the American Society of Pediatric Hematology / Oncology and the Pediatric Academic Societies

9:15am – 12:15pm

I302 Novel Targets and Novel Drugs: Peering Through the Pharmaceutical Pipeline

PAS/ASPHO Mini Course

Chairs: Timothy Cripe, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; and Jeffrey Toretsky, Lombardi Comprehensive Cancer Center, Washington, DC

This symposium will cover three of the major aspects of new drug development. First, we will explore the preclinical selection of appropriate targets and the models in which to test them. Second, we will explore the pharmaceutical pipeline to give participants knowledge of new clinical agents. Third, we will learn about coordinating the early stage clinical trials with regulatory agencies.

Introduction to Translational Research: Opening the Valves of the Pharmaceutical Pipeline

Timothy Cripe, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Pediatric Malignancies Provide Unique Cancer Therapy Targets

Jeffrey Toretsky, Lombardi Comprehensive Cancer Center, Washington, DC

Exploiting Genetic Defects for Targeting Oncolytic Viruses to Pediatric Cancers

Timothy Cripe, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

A Comparative and Preclinical Approach Toward Drug Development

Chand Khanna, National Cancer Institute, National Institutes of Health, Bethesda, MD

Developing Drugs in the Era of Targeted Therapy

Pamela S. Cohen, Novartis Pharmaceuticals Corporation, Florham, NJ

Ask Not What CTEP Can Do for You...Moving Agents Through the Pipeline

Barry Anderson, National Cancer Institute, National Institutes of Health, Rockville, MD

Special Delivery: Novel Approaches and Challenges to Gene Delivery

Mark Kay, Stanford University Medical Center, Stanford, CA

Sponsored jointly by the American Society of Pediatric Hematology / Oncology and the Pediatric Academic Societies

11:45am – 2:45pm

1403 Pain and Symptom Management in Pediatric Palliative and End-of-Life Care

PAS Mini Course

Chair: Nancy Hutton, Johns Hopkins University School of Medicine, Baltimore, MD

Many children living with chronic and life-threatening conditions experience pain and other distressing symptoms. Control of pain and symptoms is the foundation upon which competent palliative care is built. Yet children and families suffer when they encounter pediatricians and other professionals who are ill-prepared to offer them competent and compassionate palliative and end-of-life care. The Institute of Medicine (IOM) report on Improving Palliative and End-of-Life Care for Children and Their Families (2002) calls upon pediatric health professionals to address the needs of children and families for comprehensive palliative care services. In addition, routine assessment and management of pain is now a required component of patient care according to the Joint Commission for the Accreditation of Health Care Organizations (JCAHO). This session will outline basic tenets of pain and symptom management for children and adolescents, their implementation across care settings and consideration of the continued barriers to full implementation of these care standards.

Assessment and Management of Pain in Children and Adolescents

Neil L. Schechter, St. Francis Hospital and Medical Center, Hartford, CT

Reducing Barriers to Effective Pain and Symptom Management at the End of Life

Nancy Hutton, Johns Hopkins University School of Medicine, Baltimore, MD

Palliative Pain and Symptom Management in Pediatric Tertiary Care Settings

Joanne Wolfe, Dana-Farber Cancer Institute and Children's Hospital, Boston, MA

Pediatric Pain and Symptom Management in Home Care and Hospice

Speaker to be determined

1:00pm – 3:00pm

Hematology/Oncology Platform Session I

PAS/ASPHO Original Science Abstracts

3:15pm – 5:15pm

1602 Disorders of Neutrophil Number and Function

PAS/ASPHO Topic Symposium

Chair: Laurence A. Boxer, Mott Children's Hospital, University of Michigan, Ann Arbor, MI

The program will highlight new developments in clinical management of patients with chronic granulomatous disease as well as an update on the progress of gene therapy of CDG stem cells. There will also be an update on the management and diagnosis of patients with the Shwachman-Diamond syndrome, and, finally, there will be an update on diagnosis, treatment and pathophysiology of severe chronic neutropenias.

Severe Chronic Neutropenia Pathogenesis and Treatment

David Dale, University of Washington, Seattle, WA

Shwachman-Diamond Syndrome Pathogenesis and Treatment

Melvin H. Freedman, Hospital for Sick Children, Toronto, Canada

Chronic Granuloma Disease, Pathogenesis, Management

Harry Malech, National Institutes of Health, Bethesda, MD

Sponsored jointly by the American Society of Pediatric Hematology / Oncology and the Pediatric Academic Societies

5:15pm – 7:15pm

Hematology/Oncology Posters I

PAS Posters I, Exhibits and PAS Opening Reception

PAS/ASPHO Original Science Abstracts

Sunday, May 2

7:00am – 8:00am

Meet the Professor Breakfasts



The purpose of these sessions is to provide trainees and junior faculty the opportunity to meet with senior academic physicians who can provide insights in their field and provide career guidance in a small interactive group. Attendance at each session is limited and available on a first-come, first-served basis to maintain an intimate interactive format. *Pre-enrollment is not required but sessions are small and seating is on a first-come, first-served basis.*

7:00am – 8:00am

2152 Hematology / Oncology

Meet the Professor Breakfast

Valerie P. Castle, University of Michigan, Ann Arbor, MI

For information visit our website (www.pas-meeting.org) in early 2004.

8:00am – 10:00am

Hematology/Oncology Platform Session II

PAS/ASPHO Original Science Abstracts

10:15am – 11:45am

2440 Hematology/Oncology Platform Session III

PAS/ASPHO Original Science Abstracts

11:45am – 1:45pm

Hematology/Oncology Posters II

PAS Posters II and Exhibits

PAS/ASPHO Original Science Abstracts

2:00pm – 4:00pm

2702 Complications Following Solid Organ Transplantation

PAS/ASPN/LWPES/PIDS Topic Symposium

Chairs: Ellis Avner, Case Western Reserve University, Cleveland, OH; Marsha Davenport, University of North Carolina, Chapel Hill, NC; and Laurence Givner, Wake Forest University School of Medicine, Winston-Salem, NC

Despite the dramatic increase in patient and graft survival following solid organ transplantation over the past decade, complex and potent immunosuppressive regimens have led to significant complications. In this multidisciplinary symposium, the pathophysiology and therapy of infections, lymphoproliferative disease and growth abnormalities following solid organ transplantation will be reviewed. In addition, the problem of non-compliance with complex immunosuppressive regimens—a major cause of organ loss/dysfunction post transplantation—will be reviewed.

ASPHO Programming

Infections Following Solid Organ Transplantation

Michael Green, University of Pittsburgh School of Medicine, Pittsburgh, PA

Post-transplant Lymphoproliferative Disease: Pathophysiology and Treatment

Vikas R. Dharnidharka, University of Florida Health Science Center, Gainesville, FL

Growth Disorders Following Solid Organ Transplantation

Leona Cuttler, Case Western Reserve University, Cleveland, OH

Compliance with Complex Medical Regimens Post-transplantation: Anticipatory Therapies

Robert Wells, Children's Hospital Central California, Fresno, CA

Sponsored jointly by the American Society of Pediatric Nephrology, Lawson Wilkins Pediatric Endocrine Society, Pediatric Infectious Diseases Society and the Pediatric Academic Societies

2:30pm – 4:00pm

2801 Infections of the Immunocompromised Host

PAS/ASPHO/PIDS State of the Art

Chair: Nancy Bunin, Children's Hospital of Philadelphia, Philadelphia, PA

This symposium will cover new methods to detect fungal infections and indications for new drugs. CMV detection and treatment outcome will be discussed in the post-HSCT patient. Finally, other viral infections that can cause significant morbidity in the immunocompromised patient, such as HHV6 and adenovirus, will be discussed.

Introduction

Nancy Bunin, Children's Hospital of Philadelphia, Philadelphia, PA

New Approaches to Diagnosis and Treatment of Invasive Fungal Infections in Immunocompromised Pediatric Patients

Thomas Walsh, National Cancer Institute, Bethesda, MD

New Developments in the Diagnosis and Management of CMV and Adenovirus Infection in Stem Cell Transplant Recipients

Michael Boeckh, Fred Hutchinson Cancer Research Center, Seattle, WA

HHV6 Infections in Immunocompromised Patients

Danielle Zerr, Children's Hospital and Regional Medical Center, Seattle, WA

Discussion

Sponsored jointly by the American Society of Pediatric Hematology / Oncology; Pediatric Infectious Diseases Society and the Pediatric Academic Societies

4:15pm – 6:15pm

2900 Emerging Trends in Hematopoietic Stem Cell Transplantation for Primary Immunodeficiencies

PAS/ASPHO Topic Symposium

Chairs: K. Scott Baker, University of Minnesota, Minneapolis, MN; and Nancy Bunin, Children's Hospital of Philadelphia, Philadelphia, PA

This program will focus on emerging trends in hematopoietic stem cell transplantation for children with primary immunodeficiencies. Topics to be covered will include the use of alternative donor sources such as unrelated cord blood, new approaches with lower intensity pre-transplant conditioning regimens and an update on transplant outcomes for some of the more common primary immunodeficiencies such as SCID, WAS and HLH.

Hematopoietic Stem Cell Transplant for Primary Immunodeficiency Disorders: Update of Outcomes and Unrelated Cord Blood

Alexandra H. Filipovich, Children's Hospital Medical Center, Cincinnati, OH

Nonmyeloablative Stem Cell Transplant for Congenital Immunodeficiencies

Kanchana Rao, Great Ormond Street Hospital for Children, London, United Kingdom

Hematopoietic Stem Cell Transplant for Hemophagocytic Lymphohistiocytosis: Results from the Multi-institutional National Marrow Donor Program HLH Protocol

K. Scott Baker, University of Minnesota, Minneapolis, MN

Sponsored jointly by the American Society of Pediatric Hematology / Oncology and the Pediatric Academic Societies

**Visit the American
Society of Pediatric
Hematology/Oncology at
www.aspho.org**

ASPH/O

The American Society of
Pediatric Hematology/Oncology

For additional information, contact ASPH/O at:

4700 W. Lake Avenue

Glenview, IL 60025

Phone: 847-375-4716

Fax: 888-508-7578

Email: info@aspho.org

Url: www.aspho.org